A Phase 3 interventional study of Intravitreal Aflibercept Injection 2mg in Neovascular Age-related Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Completed at 124 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-03-23.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 13th largest by enrollment, is the only one that started in 2009, is one of 18 in phase 3, and was the 6th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 1 started in 2009.
This study's enrollment of 323 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
17 studies in Macular Degeneration by Regeneron Pharmaceuticals: 2 open now, 3 under way, 2 of them phase 3. Of 14 finished, 9 (64%) have results posted.
Among the 17 studies in Macular Degeneration by Regeneron Pharmaceuticals, this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2009, is one of 5 in phase 3, and was the 6th registered.
Regeneron Pharmaceuticals’s Macular Degeneration studies by the year they started, since 2005.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Regeneron Pharmaceuticals’s 17 in Macular Degeneration:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to assess long-term safety and tolerability of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in patients with neovascular AMD.
The dose evaluated in this study, Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) 2mg, will be the higher of the 2 dose strengths evaluated in parent study VGFT-OD-0605 (NCT00509795) and is the dose level administered in study VGFT-OD-0702 (NCT00527423), a long-term open-label extension study. For these reasons, this dose has been selected for this extension study.
Participants will be seen in the clinic for quarterly visits starting with day 1 to assess safety. Study drug will be administered on an as-needed basis at the discretion of the investigator with a minimum allowed interval of every 4 weeks and a maximum allowed interval of every 12 weeks. This study will assess the frequency that re-treatment is needed and the effect of continued Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) treatment on BCVA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) 2mg (40 mg/mL) was administered no more frequently than every 4 weeks, but no less frequently than every 12 weeks until amendment 4. Starting with amendment 4, Intravitreal Aflibercept Injection was administered no less frequently than every 8 weeks. Within these limits, the investigator would determine the interval of Intravitreal Aflibercept Injection administration on an as-needed basis according to the protocol-suggested re-treatment criteria, however the injections must have occurred at least every 12 weeks prior to amendment 4, and at least every 8 weeks starting from amendment 4 as noted above.
Drug: Intravitreal Aflibercept Injection 2mg
Also known as: IAI; EYLEA®; BAY86-5321; VEGF Trap-Eye
Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD
The primary endpoint in the study is the safety and tolerability of Intravitreal Aflibercept Injection in patients with neovascular AMD (Age-related Macular Degeneration) from day 1 through the end of treatment visit (week 180) based on the number of participants who experienced any treatment-emergent adverse event (TEAE). Treatment-emergent adverse events were categorized according to Ocular TEAEs in the study eye, Ocular TEAEs in the fellow eye, and Non-Ocular TEAEs
Time frame: Baseline (day 1) through end of treatment (Week 180)
Change in BCVA Letter Score (mLOCF)
The secondary endpoint in the study is the change in BCVA letter score from baseline through Week 116. (mLOCF: The last non-missing observation prior to the missing visit was carried forward to impute the missing data; no imputation after last visit; no baseline value carried forward).
Time frame: Baseline through Week 116
Summary of Treatment Duration (Weeks)
Treatment Duration = (last dose date - first dose date + 28)/7
Time frame: Baseline through end of treatment (Week 180)
Summary of Study Duration (Weeks)
Study Duration = (last visit/ discontinuation date - first dose date + 28)/7
Time frame: Baseline through end of treatment (Week 180)
After informed consent was obtained, the 323 participants who completed the parent study, VGFT-OD-0605 (NCT00509795), and met the protocol eligibility criteria, were enrolled at 71 clinical sites in the US \& Canada. The first visit occurred concurrently with the last visit in the parent study. The last participant entered this study on 18-May-2011.
| Milestone | Open-label Intravitreal Aflibercept Injection |
|---|---|
| Started | 323 |
| Number of participants treated | 320 |
| Completed | 16 |
| Not completed | 307 |
| Withdrew: Withdrawal by subject | 79 |
| Withdrew: Adverse event | 12 |
| Withdrew: Death | 14 |
| Withdrew: Lost to follow-up | 7 |
| Withdrew: Termination of study by sponsor | 169 |
| Withdrew: Unwilling to sign icf for amendment 4 | 3 |
| Withdrew: Other | 23 |
The primary endpoint in the study is the safety and tolerability of Intravitreal Aflibercept Injection in patients with neovascular AMD (Age-related Macular Degeneration) from day 1 through the end of treatment visit (week 180) based on the number of participants who experienced any treatment-emergent adverse event (TEAE). Treatment-emergent adverse events were categorized according to Ocular TEAEs in the study eye, Ocular TEAEs in the fellow eye, and Non-Ocular TEAEs
| participants | Open-label Intravitreal Aflibercept Injection |
|---|---|
| Number of participants with any TEAE | 290 |
| Any ocular TEAE | 239 |
| Any ocular TEAE: Study eye | 204 |
| Any ocular TEAE: Fellow eye | 169 |
| Any non-ocular TEAE | 232 |
| Any serious TEAE | 105 |
| Discontinuation of study due to AE | 12 |
| Any Death due to TEAE | 17 |
The secondary endpoint in the study is the change in BCVA letter score from baseline through Week 116. (mLOCF: The last non-missing observation prior to the missing visit was carried forward to impute the missing data; no imputation after last visit; no baseline value carried forward).
| letters correctly read | Open-label Intravitreal Aflibercept Injection |
|---|---|
| Change in BCVA Letter Score (mLOCF) | -2.7 ± 12.50 |
Treatment Duration = (last dose date - first dose date + 28)/7
| weeks | Open-label Intravitreal Aflibercept Injection |
|---|---|
| Summary of Treatment Duration (Weeks) | 110.4 ± 42.16 |
Study Duration = (last visit/ discontinuation date - first dose date + 28)/7
| weeks | Open-label Intravitreal Aflibercept Injection |
|---|---|
| Summary of Study Duration (Weeks) | 116.9 ± 44.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-label Intravitreal Aflibercept Injection | — | 105/323 (32.5%) | 102/323 (31.6%) |
| Event | Open-label Intravitreal Aflibercept Injection |
|---|---|
| FallInjury, poisoning and procedural complications | 16/323 |
| Atrial FibrillationCardiac disorders | 12/323 |
| SyncopeNervous system disorders | 8/323 |
| Acute Myocardial InfarctionCardiac disorders | 5/323 |
| PneumoniaInfections and infestations | 5/323 |
| Urinary Tract InfectionInfections and infestations | 5/323 |
| Cerebrovascular AccidentNervous system disorders | 5/323 |
| Cardiac ArrestCardiac disorders | 4/323 |
| Coronary Artery DiseaseCardiac disorders | 4/323 |
| Myocardial InfarctionCardiac disorders | 4/323 |
| Event | Open-label Intravitreal Aflibercept Injection |
|---|---|
| Retinal HaemorrhageEye disorders | 39/323 |
| Retinal HaemorrhageEye disorders | 34/323 |
| Age-Related Macular DegenerationEye disorders | 30/323 |
| Conjunctival HaemorrhageEye disorders | 30/323 |
| HypertensionVascular disorders | 29/323 |
| FallInjury, poisoning and procedural complications | 23/323 |
| NauseaGastrointestinal disorders | 22/323 |
| NasopharyngitisInfections and infestations | 22/323 |
| Upper Respiratory Tract InfectionInfections and infestations | 20/323 |
| BronchitisInfections and infestations | 19/323 |
Randomized participants included all participants who were enrolled in the study. The data were used to analyze the safety and efficacy parameters to characterize the long-term effect of Intravitreal Aflibercept Injection treatment. The average study duration for all enrolled participants was 116.9 weeks.
| Age, Continuous(years) | Open-label Intravitreal Aflibercept Injection |
|---|---|
| Mean | 79 ± 7.83 |
| Sex: Female, Male(Participants) | Open-label Intravitreal Aflibercept Injection |
|---|---|
| Female | 196 |
| Male | 127 |
Showing the first 100 of 124 sites across 2 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2009, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept